Abstracts

2019


- Sweeney C, Martin AJ, Zielinski RR, Thomson A, Tan TH, Sandhu SK, Reaume MN,


2018


EORTC-NCI-AACR SYMPOSIUM. 2018.


2017


35(Suppl; abstr TPS3621). 2017.


- Ledermann JA, Embleton AC, Perren T, Jayson GC, Rustin GJS, Kaye SB, Hirte HW, Oza AM, Vaughan MM, Freidlander M, Martin AG, Clark E, Popoola BO, Farrelly L,


- Ruppert AS, Byrd JC, Heerema NA, Smith MR, Godwin JE, Couban S, Fehniger TA,


• Cheung WY, Mittmann N, Leighl NB, Cheung MC, Bradbury PA, Ng RCH, Chen BE, Ding K, Pater JU, Tu D, Hay AE. The economic impact of the transition from branded to generic oncology drugs. J Clin Oncol 34[Suppl; abstr 6520]. 2016.


• de Boer SM, Powell ME, Mileshkin LR, Katsaros D, Bessette P, Haie-Meder C,


2015


- Parimi S, Karachiwala H, Lin Y, Monzon JG, Tam VC, Chen EX, Dancey J, Tang PA. Critical assessment of phase 0 (Ph0) and window of opportunity (WOO) trials: Definitions and reporting. J Clin Oncol 33[suppl; abstr e17710].


- Penniment MG. Full report of the TROG 03.01, NCIC CTG ES2 multinational phase III study in advanced esophageal cancer comparing palliation of dysphagia and quality of life in patients treated with radiotherapy or chemoradiotherapy. J Clin Oncol 33[(suppl 3; abstr 6)]. 2015.

- Qu MXL, Ramjeesingh R, Ogundimu O, Ren K, Hurlburt D, Biagi JJ, Mahmud A.


2014


- Tang PA, Hay AE, O’Callaghan CJ, Mittmann N, Chambers C, Pater JL, Leightl NB. Estimation of drug cost avoidance (DCA) and pathology cost avoidance (PCA) through


2013


Hay AE, Klimm B, Chen BE, Goergen H, Shepherd LE, Fuchs M, Gospodarowicz M,


- Moy B, Tu D, Richardson H, Maunsell E, Goss PE. NCIC CTG MAP.3: Symptoms and quality of life (QoL) among racial/ethnic minority women taking the aromatase inhibitor (AI) exemestane (EXE) for breast cancer risk reduction. J Clin Oncol 31[suppl; abstr 6557], 2013.


- Renouf DJ, Parulekar W, Grigorieva J, Tu D, Moore MJ. Assessment of the association of the VeriStrat test with outcomes in patients (pts) with advanced pancreatic cancer
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

(2012)


2012


• Chapman J-AW, Sgroi D, Goss PE, Richardson E, Binns SN, Zhang Y, Schnabel CA, Erlander MG, Pritchard KI, Han L, Shepherd LE, Pollak MN. Prognostic relevance of statistically standardized estrogen receptor (ER), progesterone receptor (PR), and


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Liedke PER, Chavarri-Guerra Y, Shepherd LE, Tu D, Pritchard KI, Goss PE. Vasomotor (VM) and musculoskeletal (MSK) symptoms and association with outcomes on extended adjuvant letrozole therapy: Analyses from NCIC CTG MA.17. J Clin Oncol 30[suppl, abstr 524], 2012.


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

be? Canadian Assoc Rad Oncol [abstr 61], 2012.

- Steele R, Quirke P, Grieve R, Monson J, Couture J, de Metz C, Pugh C, Nichols L, Thompson LC, Sebag-Montefiore D, on behalf of all investigators MCTUL. Long Term Outcome After Anastomotic Leak and the Impact of Short Course Pre-Operative Radiotherapy - Data from the MRC CRO7 NCIC CO16 trial. 6th European Multidisciplinary Colorectal Cancer Congress, 2012.
- Vogl SE, Altwairgi AK, Chapman J-AW, Zhu L, Shepherd LE, Goss PE. Characterization of patients who received further adjuvant endocrine therapy after 5 years of aromatase


2011


• Alberts SR, Thibodeau SN, Sargent DJ, Mahoney MR, Sinicrope F, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Quesenberry JT, Smyrk TC, Grothey A, Nair SG. Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS)


- Goss PE, Ingle JN, Chapman JW, Ellis MJ, Sledge GW, Budd GT, Rabaglio M, Gelmon


- Li X, Chen J, Wu Y, Tu D. Variable selections in the Cox proportional hazards model based on extended bayesian information criteria. 32nd Annual Conference of the International Society for Clinical Biostatistics, 2011.


- Meyer RM, Gospodarowicz M, Connors JM, Pearcey RG, Wells WA, Winter JN, Horning


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2010


- Alberts SR, Sargent DJ, Smyrk TC, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Thibodeau SN, Nair S. Adjuvant mFOLFOX6 with or without cetuximab in KRAS wild-type patients with resected stage III colon cancer: Results


- Eisenhauer E. In search of intermediate endpoints. EORTC-NCI-AACR Symposium [abstr 29], 2010.


- Goodwin RA, Jamal R, Booth CM, Goss PE, Eisenhauer EA, Tu D, Shepherd LE. Effects of diabetes, hypertension and coronary artery disease on prognosis after 5 years


- Liu G, Cheng D, Le Maître A, Liu N, Chen Z, Seymour L, Ding K, Shepherd FA, Tsao MS. EGFR and ABCG2 polymorphisms as prognostic and predictive markers in the


- Radich JP, Kopecky KJ, Kamel-Reid S, Stock W, Paietta E, Wadleigh M, Larson RA,
Emanuel PD, Tallman MS, Lipton J, Couban S, Deininger MW, Appelbaum FR, Druker BJ. A Randomized Phase II Trial of Dasatinib 100 Mg Vs Imatinib 400 Mg In Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): The S0325 Intergroup Trial. Blood (ASH Annual Meeting Abstracts) 116[21, LBA 6], 2010.


• Vachon CM, Brandt KR, Suman VJ, Weinshilboum R, Kosel ML, Wu F, Serie DJ, Olson


2009


Craddock KJ, Buys TPH, Zhu CQ, Strumpf D, Pintillie M, Ding K, Seymour L, Jurisica I, Shepherd FA, Lam WL, Tsao M-S. High resolution genomic analysis of NSCLC reveals regions of DNA copy number gain that may be predictive of benefit from adjuvant chemotherapy. J Thoracic Oncol 4[9 suppl 1, abstr PD12.2.6], S580. 2009.


important predictors of outcome in older multiple myeloma patients treated with melphalan and corticosteroids; subgroup analysis from the National Cancer Institute of Canada MY7 trial. International Society of Geriatric Oncology, 2009.


- Palmer M, Broxtermann J, Shepherd L, Parulekar W. Tracking patients on an intergroup oncology study. It's a snap! Clinical Trials 6, 536, 2009.


• Stearns V, Chapman J-A, Ma C, Ellis MJ, Ingle J, Pritchard KI, Budd GT, Rabaglio M,


2008

- Bradbury PA, Tu D, Seymour L, Ng R, Zhu L, Isogai PK, Mittmann N, Evans WK,


Pollak MN, Chapman JW, Pritchard KI, Krook JE, Dhaliwal HS, Vandenbarg TA, Norris
Abstracts  
Published on Canadian Cancer Trials Group  
(https://www.ctg.queensu.ca)


- Schell AJ, Young I, Hansen C, Chi KN, Taylor S. BRAF mutation status and growth factor receptor expression do not predict baseline factors or outcome in hormone refractory prostate carcinoma. United States and Canadian Academy of Pathology, 2008.
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2007


- Arnold AM, Smylie M, Ding K, Ung Y, Findlay B, Lee CW, Djurfeldt M, Seymour L, Langmuir P, Shepherd F. Randomized phase II study of maintenance vandetanib (ZD6474) in small cell lung cancer patients who have a complete or partial response to


Tsao M. Predictors of benefit from targeted therapy: lessons learned from the EGFR

- Tu D. Identification of patients who will benefit from a treatment based on their genetic profiles: Some examples and statistical issues. Workshop on Statistical Analysis of High-Throughput Genetic Data, 2007.

2006


- O’Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman DG, Bramwell VH, Andrulis I, Pritchard KI. Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). Breast Cancer Research and Treatment 100[Suppl 1], S18, 2006.


Shepherd LE, Parulekar W, Pritchard KL, Trudeau M, Paul N, Tu D, Levine M. Left ventricular function following adjuvant chemotherapy for breast cancer: The NCIC CTG


2005


- Goss PE, Ingle JN, Palmer MJ, Shepherd LE, Tu D. Updated analysis of NCIC CTG MA.17 (letrozole vs placebo to letrozole vs placebo) post unblinding. Breast Cancer
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Li D. Determinants of sample size and power in equivalence trials that compare binomial outcomes. Clinical Trials 2[Suppl 1], SS9, 2005.
- Li D. Can more frequent regular group sequential tests help to make an earlier conclusion in clinical trials? A retrospective evaluation. Clinical Trials 2[Suppl 1], 2005.
- Messerschmidt T, Koski B. Integrating SOPs into a comprehensive website document management system. Clinical Trials 2[Suppl 1], S50, 2005.

- Tu D. Nonparametric estimate and confidence intervals for the hazard ratio based on censored data. Clinical Trials 2[Suppl 1], S36, 2005.

2004

- Chi K, Eisenhauer E, Fazli L, Jones EC, Powers J, Hurtado-Coll A, Goldberg L,


- Ding K. Point estimate following group sequential tests. ENAR Int Biometric Soc, 2004.


• O'Sullivan B, Davis A, Turcotte R, Bell R, Wunder J, Catton C, Hammond A, Freeman C,


- Sloan JA, McLeod H, Sargent DJ, Zhao X, Fuchs CS, Ramanathan RK, Williamson SK, Findlay B, Morton RF, Goldberg RM. Preliminary Evidence of Relationship Between
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

Genetic Markers and Oncology Patient Quality of Life (QoL). International Society for Quality of Life Research [abstr 146], 2004.


2003


- Ding K, Hall WJ. Sequential test and estimates after overrunning based on p-value
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


Mazumdar M, Tu D. Efficiency of STRTA matched case-control studies with multiple controls per case in survival data setting. Controlled Clin Trials 24(3S), 112S, 2003.


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2002

Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

- Goldberg RM, Morton RF, Sargent DJ, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP. N9741: oxaliplatin or CP-11 + 5-fluorouracil/leucovorin or oxal + CPT-11 in


• Savage C, Pater J, Tu D, Norris B. He said/she said: how much agreement is there on


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- O'Connell M, Skillings J, Windschitl H, Shepherd L, Sargent D, Krook J, Tria Tirona M,


1999


- Moore M, Belanger K, Jolivet J, Baker S, Wainman N, Seymour L. NCIC CTG IND 103:


1998

1998.
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Zee B, Eisenhauer E. Design issues of phase II cancer clinicaltrials with multiple
Abstracts
Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)


1997

- Dent S, Klaassen D, Pater J, Zee B, Whitehead M. Update of second primary
malignancies and treatment results in women with early stage ovarian cancer.


- Tu D, Zee B, James K, Palmer M, Pater J. Numbers of events needed in comparing survival data to a standard population using the subjects-years method. Controlled
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Tu D. Statistical procedures in therapeutic equivalence clinical trials with ordered
- van Glabbeke M, Vermorken J, Eisenhauer E. Predictors of survival and time to
progression following second- or third-line treatment in advanced ovarian cancer: an
analysis of 744 patients treated with paclitaxel, docetaxel or high dose epirubicin.
survival analysis of interferon maintenance in multiple myeloma.
- Zee B. Imputation methods for quality of life data with missing values in cancer clinical

1996

- Bacon M, Myles J, Fiander W, Thunberg P, Craig C, Papakonstantinou C, Desjardins L,
Dionne J, Cowperthwaite B, Johnston N, Binder H, Laamanen M, Sinnott C, McDonald
K, Bartel J, Thain C, Green D, Shepert L. Do pre existing biologic characteristics
influence chemotoxicities and thus, nursing intervention plans? International Conference
on Cancer Nursing, 1996.
- Cripps C, Osoba D, Zee B. Gender differences in responses to the EORTC quality of life
- Cripps C, Osoba D, Zee B. Gender differences in responses to the EORTC quality of life
- Crump M, Lipton J, Hedley D, Scott J, Sutton D, Keating A, Minden M, Messner H,
Eisenhauer E. A phase I trial of sequential topotecan and etoposide in adult acute
- Crump M, Lipton J, Hedley D, Eisenhauer E. A phase I trial of sequential topotecan and
- Dent S, Zee B, Dancey J, Melnychuck D, Eisenhauer E, Steward W, Lu F. Design of
7(Suppl 1), 134, 1996.
- Eisenhauer E, Blackstein M, Forsyth P, Wainman N, Beare S. Phase II trials of
docetaxel in patients with malignant glioma and soft tissue sarcoma. Ann.Oncol. 7(Suppl
1), 96, 1996.
- Findlay B, Tonkin K, Crump M, Norris B, Trudeau M, Blackstein M, Burnell M, Skillings J,
Bowman D, Walde D, Levine M, Palmer M, Myles J, James K. A dose escalation trial of
adjuvant CEF chemotherapy with G-CSF for premenopausal women with node-positive
A phase II trial of docetaxel in patients with recurrent malignant glioma. Proceedings
- Hall R. for MRC Advanced Bladder Cancer Working Party, EORTC GU Group, NCI
Canada, Norwegian Bladder Cancer Group, Australian Bladder Cancer Study Group,
Club Urologica Espanol de Tratamiento and FinBladder. Neo-adjuvant CMV


and NCIC CTG.) Phase III randomized study of all-trans retinoic acid versus daunorubicin and cytosine arabinoside as induction therapy and all-trans retinoic acid versus observation as maintenance therapy for patients with previously untreated acute promyelocytic leukemia. Blood (ASH Annual Meeting Abstracts) 86[10 Suppl 1], 1996.

- Zee B. Phase II design for cancer clinical trials using multivariate endpoints. Biometric Society ENAR, 1996.

1995


• Lofters C, Zee B. Adding 5 HT3 antagonists to dexamethasone after 24 hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Eur.J.Can. 31A(suppl.5), 255, 1995.


• Lofters W, Zee B. Adding 5HT3 antagonists to dexamethasone after twenty four hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Supportive Care in Cancer 3(5), 339, 1995.


1994

Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Paul N. The success of clinical trials depends on good communication. Joint meeting of EORTC SGDM and BODMA, 1993.


Pater J, Niezgoda H, Zee B. Validation of the EORTC-QLC -- a comparison with four other instruments in a heterogeneous group of cancer patients. Ann.Oncol. 3(Suppl.5), 175, 1992.


1991


Johnston D. Coordinating a pivotal clinical trial: an educational experience. Controlled

1989


Palmer M, Pater J. Comparison of errors in body surface area and initial doses in five clinical trials (C0.2, C0.3, HD.4, MA.4, OV.8). Controlled Clin.Trials 10(3), 351, 1989.


Feld R, Pater J, Coy P. Restaging of responding patients with limited disease small cell...


1987

- Yelle L, Willan A, Pater J. Trial of chemotherapy and radiotherapy in advanced


O'Dwyer P, Eisenhauer E, Hoth D. Deoxycoformycin in lymphoid malignancies, an overview. NCI-EORTC Symposium on New Drugs in Cancer Therapy, 1986.


Wallenstein S, Patel HI, Willan A. Use of baseline values in the two period two treatment crossover design. Biometric Society ENAR, 1986.
1985


1984


1983


1981